C07K 2319/30
Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or fc region, or
Official title: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
C07K2319/30 (Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or fc region, or) appears on 5,710 US grants and 11,020 published applications in this corpus.
Search patents in C07K- Granted patents
- 5,710
- Published applications
- 11,020
- Assignees
- 2,371
- Inventors
- 12,781
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 3 | 0 |
| 1993 | 7 | 0 |
| 1994 | 6 | 0 |
| 1995 | 13 | 0 |
| 1996 | 20 | 0 |
| 1997 | 25 | 0 |
| 1998 | 50 | 0 |
| 1999 | 48 | 0 |
| 2000 | 45 | 0 |
| 2001 | 45 | 11 |
| 2002 | 47 | 152 |
| 2003 | 57 | 1383 |
| 2004 | 55 | 200 |
| 2005 | 60 | 237 |
| 2006 | 121 | 248 |
| 2007 | 262 | 228 |
| 2008 | 235 | 184 |
| 2009 | 145 | 274 |
| 2010 | 190 | 246 |
| 2011 | 159 | 262 |
| 2012 | 166 | 250 |
| 2013 | 168 | 305 |
| 2014 | 198 | 316 |
| 2015 | 197 | 327 |
| 2016 | 216 | 463 |
| 2017 | 233 | 417 |
| 2018 | 252 | 483 |
| 2019 | 289 | 572 |
| 2020 | 322 | 597 |
| 2021 | 435 | 721 |
| 2022 | 364 | 743 |
| 2023 | 337 | 647 |
| 2024 | 362 | 771 |
| 2025 | 380 | 586 |
| 2026 | 197 | 397 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- IL-10 muteins6 Oct 2026US 12,753,217 B2Universite De Lille
- Compositions and methods for modulating FLRT3 mediated signal transduction6 Oct 2026US 12,753,229 B2Nextcure, Inc.
- Drug-specific pharmacokinetic assay for IL-15 superagonist6 Oct 2026US 12,754,189 B2NantCell, Inc.
- HERV-K (HML-2) Env analog fusion proteins for antigen specific immunotherapy and methods of use29 Sep 2026US 12,747,270 B2Twilight Bioscience, Inc.
- Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof29 Sep 2026US 12,747,279 B2Abelzeta Inc.
- Fgf21 compound / glp-1r agonist combinations with optimized activity ratio8 Oct 2026US 2026/0306587 A1Sanofi
- Targeted engineered interferon and uses thereof8 Oct 2026US 2026/0308221 A1Orionis Biosciences BV
- Bispecific fusion proteins with immunosuppressive activity8 Oct 2026US 2026/0308227 A1
- Activin receptor type iib variants and uses thereof8 Oct 2026US 2026/0308229 A135PHARMA Inc.
- Recombinant fusion protein for treatment of pulmonary hypertension8 Oct 2026US 2026/0308230 A1
Most cited
By later US patents
- Recombinant immunoglobin preparations4,785US 4,816,567 AGenentech, Inc. · 1989
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997
- Humanized immunoglobulins and methods of making the same1,467US 6,180,370 B2Protein Design Labs, Inc. · 2001